AIMS AND BACKGROUND: To evaluate clinical outcome and toxicity using high-dose-rate brachytherapy as monotherapy in head and neck carcinomas. METHODS: Between September 2004 and April 2010, a series of 12 patients with lip (7 patients) or buccal mucosa (5 patients) cancers were treated by exclusive interstitial high-dose-rate brachytherapy. The median age of the patients was 71.5 years (range, 47-87). Stages were T1N0M0 and T2N0M0 in 6 and 6 patients, respectively. A dose of 27 to 54 Gy in 9 to 16 fractions, 3 to 4.5 Gy per fraction, 2 fractions per day with a minimal gap of 6 h in between was delivered. RESULTS: After a median follow-up of 46 months (range, 10-85), the disease-free and overall survival was 83% (10 of 12 patients) and 50% (6 of 12 patients), respectively. The crude local control in the lip cancer patients was 100% and in the buccal mucosa cancer patients was 60%. No severe toxicity was registered. CONCLUSIONS: High-dose-rate brachytherapy is feasible and safe and offers the possibility to treat patients in an outpatient regimen

High-dose-rate interstitial brachytherapy in early stage buccal mucosa and lip cancer: report on the consecutive 12 patients and review of the literature / A. Vavassori, F. Gherardi, S.P. Colangione, C. Fodor, F. Cattani, R. Lazzari, L. Calabrese, R. Bruschini, D. Alterio, B.A. Jereczek-Fossa, R. Orecchia. - In: TUMORI. - ISSN 0300-8916. - 98:4(2012), pp. 471-477.

High-dose-rate interstitial brachytherapy in early stage buccal mucosa and lip cancer: report on the consecutive 12 patients and review of the literature

S.P. Colangione;B.A. Jereczek-Fossa
Penultimo
;
R. Orecchia
Ultimo
2012

Abstract

AIMS AND BACKGROUND: To evaluate clinical outcome and toxicity using high-dose-rate brachytherapy as monotherapy in head and neck carcinomas. METHODS: Between September 2004 and April 2010, a series of 12 patients with lip (7 patients) or buccal mucosa (5 patients) cancers were treated by exclusive interstitial high-dose-rate brachytherapy. The median age of the patients was 71.5 years (range, 47-87). Stages were T1N0M0 and T2N0M0 in 6 and 6 patients, respectively. A dose of 27 to 54 Gy in 9 to 16 fractions, 3 to 4.5 Gy per fraction, 2 fractions per day with a minimal gap of 6 h in between was delivered. RESULTS: After a median follow-up of 46 months (range, 10-85), the disease-free and overall survival was 83% (10 of 12 patients) and 50% (6 of 12 patients), respectively. The crude local control in the lip cancer patients was 100% and in the buccal mucosa cancer patients was 60%. No severe toxicity was registered. CONCLUSIONS: High-dose-rate brachytherapy is feasible and safe and offers the possibility to treat patients in an outpatient regimen
Buccal mucosa cancer; HDR brachytherapy; Lip cancer; Oral cavity cancer
Settore MED/36 - Diagnostica per Immagini e Radioterapia
Article (author)
File in questo prodotto:
Non ci sono file associati a questo prodotto.
Pubblicazioni consigliate

Caricamento pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/2434/202215
Citazioni
  • ???jsp.display-item.citation.pmc??? 1
  • Scopus 2
  • ???jsp.display-item.citation.isi??? 4
social impact